Eli Lilly Says 52-Week Data from TOGETHER-PsO and TOGETHER-PsA Phase 3b trials of the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) Vs. Taltz Alone Shows Improved and Durable Efficacy in Patients With Psoriatic Disease and Obesity
At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically superior improvements versus Taltz alone were observed in the TOGETHER-PsO and TOGETHER-PsA trials
Systemic inflammation and metabolic outcomes continued to improve or were sustained at one year with Taltz and Zepbound compared to Taltz alone in pre-specified, exploratory endpoints
Data from first-of-their-kind studies contribute to the understanding of immunometabolic health
Login to comment